CCL Products (India) (CCL) Q3 25/26 earnings summary

Executive summary

• Achieved Q3 consolidated turnover of INR 1,053 crore, up 38% year-over-year; nine-month turnover at INR 3,239.41 crore, up 42% year-over-year.

• Q3 consolidated net profit reached INR 100.26 crore, up 59% year-over-year; nine-month net profit at INR 273.57 crore, up 31% year-over-year.

• Interim dividend of INR 2.75 per equity share declared for FY 2025-26, with record date set for February 10, 2026.

• Un-audited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025, were approved and reviewed by statutory auditors with unmodified reports.

• Domestic market gross sales for Q3 at INR 180 crore, with branded sales contributing INR 120 crore.

Financial highlights

• Q3 EBITDA at INR 187.56 crore, up 47% year-over-year; nine-month EBITDA at INR 547.6 crore, up 38%.

• Q3 PBT at INR 116.27 crore, up 62% year-over-year; nine-month PBT at INR 337.55 crore, up 37%.

• Standalone Q3 revenue from operations: Rs. 56,429.43 lakhs; nine months: Rs. 1,65,828.53 lakhs.

• Standalone Q3 net profit: Rs. 3,624.90 lakhs; nine months: Rs. 17,987.54 lakhs.

• Free cash flow for the trailing twelve months at approximately INR 700 crore.

Outlook and guidance

• Volume growth guidance remains at 18%-20% for the year; next year’s guidance to be updated post market developments.

• EBITDA growth guidance revised to approximately 25% for the year, with 15%-20% targeted for the next year, subject to market conditions.

• Management continues to monitor regulatory changes, especially new Labour Codes, and has made provisions for potential impacts.

• Expect to reach 85%-90% capacity utilization in two years, with future capacity expansion under consideration.